Bill Russell and Jim Rieker are survivors. Both diagnosed with bladder cancer, the men have made it their mission to help ...

Join leading experts to discuss how we are ushering in a new era in bladder cancer care on May 28 virtually. Register now.

UroGen Pharma ( NASDAQ: URGN) announced on Wednesday that the U.S. FDA has scheduled an Oncologic Drugs Advisory Committee ...

Imfinzi plus BCG induction and maintenance therapy showed a statistically and clinically meaningful improvement in DFS for ...

Durvalumab plus full BCG significantly improved disease-free survival in high-risk early bladder cancer vs BCG alone in the ...

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi ...

Discover a study where patients reported a high severity of treatment side effects than anticipated by their clinicians.

In the POTOMAC study, one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance ...

Cretostimogene grenadenorepvec is an investigational oncolytic immunotherapy that is being studied for the treatment of ...

UGN-102 is being developed as a treatment for patients with recurrent low-grade, intermediate-risk non-muscle-invasive bladder cancer. During the ODAC meeting, independent medical experts will ...